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Table	1:	Screening	Guidelines	
	 At	
diagnosis,	
if	not	
previously	
obtained	
At	1-2	
year	
intervals	
and	as	
needed	
As	needed	
depending	
on	
symptoms	
or	disease	
type	
Comments	
Audiology	 *	 *	 	 	
Cardiology	
							Blood	Pressure	
							Echocardiogram	
							Electrocardiogram	
							Holter	
							Cardiac	MRI	
	
*	
*	
*	
	
*	
*	
*	
	
	
	
	
*	
*	
Holter	recording	depending	on	
the	underlying	diagnosis	and	
risk	of	heart	block;	up	to	every	
3-6	months	for	disorders	
associated	with	high-risk	of	
arrhythmias,	such	as	mtDNA	
deletion	disorders	
	
Echocardiograms	may	be	
performed	less	frequently	in	
low-risk	patients	after	several	
years	of	monitoring	
Endocrinology	
						Basic	chemistries	
						Calcium	(Ca),	Magnesium		
													(Mg)	&	Phosphate		
						Cortisol-ACTH-		
													Aldosterone-Renin	
						Ca	&	phosphate,	urine	
						Gonadotrophins							
						Hemoglobin	A1c	
						Parathyroid	hormone	
						Thyroid	stimulating		
														hormone	&	free		
															thyroxine	
						Vitamin	D	
						Dual	X-ray		
													Absorptiometry	(DXA)	
	
*	
*	
	
	
	
*	
	
*	
*	
*	
	
	
*	
	
		
*	
*	
	
	
	
*	
	
*	
	
*	
	
	
*	
	
	
	
	
	
*	
	
	
*	
	
*	
	
	
	
	
*	
Endocrine	screening	strongly	
recommended	in	those	with	
mtDNA	deletion	disorders	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
DXA	especially	if	unexpected	
fractures	
Gastroenterology	
						Amylase-lipase	
						Transaminases	
						Stool	elastase	
						Swallow	evaluation	
	
	
	
*	
	
	
*	
	
*	
	
*	
*	
	
Growth	and	anthropometric	
parameters	
*	 *	 	 Recommended	at	each	visit	
Hematology	 	 	 	 Obtained	more	routinely	in	
those	with	high	risk	of	or	
						CBC	with	differential	
						Iron	studies	including		
						ferritin	
*	 	 *	
*	
symptomatic	bone	marrow	
dysfunction	
Immunology	 	 	 *	 With	recurrent	infections	
Neurology	
								Developmental	&		
										Cognitive	Assessments	
								Electroencephalogram	
	
*	
	
*	
	
	
	
*	
	
Clinical	appraisal	or	formal	
neuropsychological	tests;	
formal	testing	recommended	
with	regression	
Ophthalmology		
									Exam	
									Electroretinogram	
									Optical	Coherence		
															Tomography	
		
*	
	
*	
	
	
*	
*	
	
Psychiatry	
										Mood	and	Anxiety		
															Disorder	Screening	
*	 *	 	 	
Pulmonology	
							Pulmonary	function	
	
							Polysomnogram	
	 	 	
*	
	
*	
	
Especially	with	myopathy	&	if	
non-ambulatory	or	with	
brainstem	dysfunction	
Renal	
							CMP	with	Mg	and	Phos	
							Albumin/creatine,	urine	
	
			
*	
*	
	
*	
*	
	
	
	
	
	
	
	
Table	2:		Other	specialist	consultations	to	consider	at	time	of	diagnosis	and	at	1-2	year	
intervals	as	needed	based	on	symptoms	
	
Audiology	
Cardiology	
Endocrinology	
Ear,	Nose	and	Throat	
Gastroenterology	
Genetics	
Hematology	
Immunology	
Nephrology	
Neurology	
Ophthalmology	
Orthopedics	
Palliative	Care	
Physical	Medicine	&	Rehab/Physiatry	
Psychiatry	(for	patient	or	family)	
Psychology	(including	Family	Counseling)	
Pulmonology	
Social	Work	
Sleep	Medicine	
Therapy	services	including	PT,	OT	and	ST	
	
	
Table	3:		Illness,	Anesthesia	and	Stroke	Management	
	
Illness	Management3	
1. Specific	decisions	about	patient	management	including	hospitalization	require	clinical	
judgment	and	should	be	case-specific.	Decisions	should	reflect	the	individual	patient’s	
presentation	as	well	as	an	understanding	of	the	etiology	for	the	acute	decompensation	
and	the	pathophysiology	of	the	underlying	mitochondrial	disorder.	 	
2. Patients	with	a	mitochondrial	disease	should	carry	an	emergency	care	plan	that	details	
their	underlying	disorder	and	provides	management	recommendations.	 	
3. Patients	with	a	mitochondrial	disease	should	consider	wearing	a	Medic	Alert	bracelet	
when	appropriate	depending	on	their	clinical	symptomology.	 	
4. Mitochondrial	patients	should	take	precautions	to	prevent	entering	catabolism,	
especially	when	exposed	to	medical	stressors,	including	avoiding	prolonged	fasting	and	
receiving	dextrose-containing	intravenous	(IV)	fluids	before,	during,	and	after	
procedures	and	surgeries.	(Dextrose	should	not	be	provided	or	provided	in	limited	
quantity	as	indicated	by	clinical	status	in	suspected	or	confirmed	disorders	of	pyruvate	
metabolism,	if	the	patient	is	on	a	ketogenic	diet,	or	the	patient	has	had	a	previous	
adverse	response	to	high	glucose	delivery.)	 	
5. Evaluation	of	a	mitochondrial	patient	in	the	acute	setting	should	include	evaluation	of	
routine	chemistries,	glucose,	transaminases,	and	lactate;	all	other	testing	is	as	clinically	
indicated,	although	one	must	keep	in	mind	the	potential	for	cardiac	and	neurologic	
decompensations	in	these	patients.	 	
6. Treatment	during	acute	decompensation	should	include	dextrose-containing	IV	fluids,	
stopping	exposure	to	potentially	toxic	medications,	and	correction	of	any	metabolic	
derangements.	(Note:	dextrose	should	be	provided	only	in	limited	in	quantity	or	not	at	
all,	as	indicated	by	clinical	status	in	suspected	or	confirmed	disorders	of	pyruvate	
metabolism,	if	the	patient	is	on	a	ketogenic	diet,	or	the	patient	has	had	an	adverse	
response	to	high	glucose	delivery.)	IV	fluid	rate	should	be	based	on	the	clinical	situation.	
Outpatient	mitochondrial	therapies	should	be	continued	when	possible.	 	
7. Lipids	can	be	used	when	needed	in	mitochondrial	patients,	even	in	the	presence	of	
secondary	fatty-acid	oxidation	dysfunction.	
8. The	following	medications	should	be	avoided	in	patients	with	mitochondrial	disease	
when	possible	and,	if	given,	they	should	be	used	with	caution:	valproic	acid;	statins;	
metformin;	high-dose	acetaminophen;	and	selected	antibiotics,	including	
aminoglycosides,	linezolid,	tetracycline,	azithromycin,	and	erythromycin.		
9. Repeat	neuroimaging	should	be	considered	in	any	mitochondrial	patient	with	an	acute	
change	in	neurologic	status.		
	
Anesthesia	and	Surgical	Management3	
1. Patients	with	mitochondrial	diseases	are	at	an	increased	risk	of	anesthesia-related	
complications.		
2. Preoperative	preparation	of	patients	with	mitochondrial	disease	is	crucial	to	their	
perioperative	outcome.	Patients	should	minimize	preoperative	fasting	and	have	glucose	
added	to	their	perioperative	IV	fluids,	unless	they	are	on	a	ketogenic	diet	or	have	been	
demonstrated	to	have	adverse	reaction	to	higher	glucose	intake.		
3. Caution	must	be	used	with	volatile	anesthetics	because	mitochondrial	patients	may	
potentially	be	hypersensitive.		
4. Caution	must	be	used	with	muscle	relaxants	in	those	mitochondrial	patients	with	a	
preexisting	myopathy	or	decreased	respiratory	drive.	
5. Mitochondrial	patients	may	be	at	a	higher	risk	for	propofol	infusion	syndrome	and	
propofol	use	should	be	avoided	or	limited	to	short	procedures. 	
6. One	should	consider	slow	titration	and	adjustment	of	volatile	and	parenteral	anesthetics	
to	minimize	hemodynamic	changes	in	mitochondrial	patients.		
7. Local	anesthetics	are	generally	well-tolerated	in	patients	with	mitochondrial	defect.		
8. There	is	no	clear	established	link	between	malignant	hyperthermia	and	mitochondrial	
disease.		
	
Stroke	Management3, 72	
1. Stroke-like	episodes	in	primary	mitochondrial	disease	typically	have	correlating	visible	
magnetic	resonance	imaging	abnormalities.		
2. IV	arginine	hydrochloride	should	be	administered	urgently	in	the	acute	setting	of	a	
stroke-like	episode	associated	with	the	MELAS	m.3243	A>G	mutation	in	the	MTTL1	gene	
and	considered	in	a	stroke-like	episode	associated	with	other	primary	mitochondrial	
cytopathies	as	other	etiologies	are	being	excluded.	Patients	should	be	reassessed	after	3	
days	of	continuous	IV	therapy.		
3. The	use	of	daily	oral	arginine	supplementation	to	prevent	strokes	should	be	considered	
in	MELAS	syndrome.		
4. The	role	of	monitoring	plasma	arginine	and	citrulline	levels	and	oral	citrulline	
supplementation	in	the	treatment	of	MELAS	requires	further	research.		
	
	
Table	4:	Medication	Cautions	
Medication	 Common	Uses	 Concern	in	Mitochondrial	
Disease	
Acetaminophen	 Analgesic,	fever	prevention,	
headaches	
Chronic	or	frequent	use	may	
deplete	glutathione	and	
cause	hepatopathy	
Aminoglycosides	 Antibiotic	 Hearing	loss	
Antiretrovirals	 HIV	therapy	 Impaired	mtDNA	replication	
and	worsening	peripheral	
neuropathy,	liver	dysfunction	
or	myopathy		
Botulinum	toxin	 Dystonia,	Spasticity	 Worsening	of	weakness	
Butterbur	 Headache	 May	contain	pyrrolizidine	
alkaloids	(oxidants)	and	
cause	hepatopathy	
Metformin	 Diabetes	 Lactic	acidosis	
Topiramate	 Epilepsy,	Headache,	
Intracranial	Hypertension			
Lactic	acidosis	
Statins	 Hypercholesterolemia	 Worsening	myopathy	and	
elevated	creatine	kinase	(CK)	
Valproic	Acid	 Epilepsy,	Headache,	Mood	
disorders,	Movement	
disorders,	Tone	
abnormalities	
Irreversible	liver	failure	and	
onset	of	hepato-
encephalopathy,	especially	in	
POLG-related	disorders;	
worsening	of	seizures	
Vigabatrin	 Epilepsy	 Inhibition	of	the	
mitochondrial	nucleoside	
salvage	pathway	and	
worsening	of	mtDNA	
depletion	disorders	
With	the	exception	of	valproic	acid	in	POLG-related	disorders,	these	medications	are	not	
contraindicated	and	may	be	used	with	caution	
	
